Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

European Journal of Cancer, Supplement · Published 2021-11-01 · DOI 10.1016/j.ejcsup.2021.06.001

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcsup.2021.06.001

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year
2021

Related articles